Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.36 |
| ▸ | CPT1A | P50416 | 2/20 | 0.36 |
| ▸ | CPT2 | P23786 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4216577 | 0.84 | RIPK1 (0.39) | HCRTR1HCRTR2GRM5ALDH1A1TSHR | |
| SCHEMBL4216573 | 0.84 | RIPK1 (0.39) | HCRTR1HCRTR2GRM5ALDH1A1TSHR | |
| SCHEMBL17069027 | 0.77 | ALDH1A1 (0.45) | HCRTR1HCRTR2MAPTALDH1A1TSHR | |
| SCHEMBL17069036 | 0.74 | HCRTR1 (0.41) | HCRTR1HCRTR2TP53MAPTGRM5 | |
| SCHEMBL17069044 | 0.72 | CYP3A4 (0.46) | HCRTR1HCRTR2TP53MAPTBAZ2A | |
| SCHEMBL17069015 | 0.72 | HCRTR1 (0.46) | HCRTR1HCRTR2GRM5 | |
| SCHEMBL18815570 | 0.72 | RIPK1 (0.41) | HCRTR1HCRTR2MAPTGRM5ALDH1A1 | |
| SCHEMBL17069048 | 0.71 | BAZ2A (0.43) | HCRTR1HCRTR2TP53MAPTCYP11B2 | |
| SCHEMBL17069026 | 0.71 | EPHX2 (0.58) | HCRTR1HCRTR2GRM5ALDH1A1CPT1A | |
| SCHEMBL3369475 | 0.69 | HCRTR1 (0.61) | HCRTR1HCRTR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493446-B2 | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-15 | — | — | US | disclosed |
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885TP53 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.